רבלימיד 5 מג ישראל - עברית - Ministry of Health

רבלימיד 5 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 10 מג ישראל - עברית - Ministry of Health

רבלימיד 10 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 10 מג ישראל - עברית - Ministry of Health

רבלימיד 10 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 15 מג ישראל - עברית - Ministry of Health

רבלימיד 15 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 15 מג ישראל - עברית - Ministry of Health

רבלימיד 15 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 25 מג ישראל - עברית - Ministry of Health

רבלימיד 25 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 25 מג ישראל - עברית - Ministry of Health

רבלימיד 25 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

אמלה % 5 ישראל - עברית - Ministry of Health

אמלה % 5

padagis israel agencies ltd, israel - lidocaine; prilocaine - קרם - lidocaine 2.5 %; prilocaine 2.5 % - prilocaine, combinations - prilocaine, combinations - topical anaesthetic for superficial dermal analgesia in connection with insertion of iv catheters, blood sampling and superficial surgical procedures.

דפאלפט סירופ ישראל - עברית - Ministry of Health

דפאלפט סירופ

cts chemical industries ltd, israel - valproic acid as sodium - סירופ - valproic acid as sodium 40 mg/ml ml - valproic acid - valproic acid - generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.

ריספונד 1 ישראל - עברית - Ministry of Health

ריספונד 1

unipharm ltd, israel - risperidone - טבליות מצופות - risperidone 1 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrania and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidone is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract